Associated Papers
Exploring the Relationship Between KRAS, NRAS, and BRAF Mutations and Clinical Characteristics in Iranian Colorectal Cancer Patients.
Mosaferi Z et al.
Journal of Gastrointestinal Cancer, 2024
KRAS Mutation Subtypes and Their Association with Other Driver Mutations in Oncogenic Pathways.
Mondal K et al.
Cells, 2024
The spectrum of MAPK-ERK pathway genomic alterations in gynecologic malignancies: Opportunities for novel therapeutic approaches.
Nasioudis D et al.
Gynecologic Oncology, 2023
Molecular Biology and Therapeutic Perspectives for K-Ras Mutant Non-Small Cell Lung Cancers.
Cekani E et al.
Cancers, 2022
Ophthalmic manifestations in Costello syndrome caused by Ras pathway dysregulation during development.
Shankar SP et al.
Ophthalmic Genetics, 2022
Identification of RAS mutant biomarkers for EGFR inhibitor sensitivity using a systems biochemical approach.
McFall T et al.
Cell Reports, 2021
Antitumor efficacy of XPO1 inhibitor Selinexor in KRAS-mutant lung adenocarcinoma patient-derived xenografts.
Rosen JC et al.
Translational Oncology, 2021
Characterization With KRAS Mutant Is a Critical Determinant in Immunotherapy and Other Multiple Therapies for Non-Small Cell Lung Cancer.
Shen M et al.
Frontiers in Oncology, 2021
Comprehensive Validation of Snapback Primer-Based Melting Curve Analysis to Detect Nucleotide Variation in the Codon 12 and 13 of KRAS Gene.
Zhang Q et al.
Biomed Research International, 2018
BRAF and NRAS Locus-Specific Variants Have Different Outcomes on Survival to Colorectal Cancer.
Summers MG et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2017
Ordering of mutations in acute myeloid leukemia with partial tandem duplication of MLL (MLL-PTD).
Sun QY et al.
Leukemia, 2017
Clinical and Molecular Characteristics of NF1-Mutant Lung Cancer.
Redig AJ et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2016
Outcomes of patients with advanced cancer and KRAS mutations in phase I clinical trials.
Said R et al.
Oncotarget, 2014
KRAS-G12C mutation is associated with poor outcome in surgically resected lung adenocarcinoma.
Nadal E et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer, 2014
Alterations of INPP4B, PIK3CA and pAkt of the PI3K pathway are associated with squamous cell carcinoma of the lung.
Stjernström A et al.
Cancer Medicine, 2014
Melting curve analysis for mutations of EGFR and KRAS.
Furugaki K et al.
Anticancer Research, 2014
Mutations in specific codons of the KRAS oncogene are associated with variable resistance to neoadjuvant chemoradiation therapy in patients with rectal adenocarcinoma.
Duldulao MP et al.
Annals of Surgical Oncology, 2013
Phenotypic analysis of individuals with Costello syndrome due to HRAS p.G13C.
Gripp KW et al.
American Journal of Medical Genetics. Part A, 2011
The RAS/MAPK syndromes: novel roles of the RAS pathway in human genetic disorders.
Aoki Y et al.
Human Mutation, 2008
Ampullary carcinoma-A genetic perspective.
Jayaramayya K et al.
Mutation Research. Reviews in Mutation Research, 0